ES2062392T3 - Medicamentos que comprenden salmeterol y fluticasona. - Google Patents

Medicamentos que comprenden salmeterol y fluticasona.

Info

Publication number
ES2062392T3
ES2062392T3 ES90309846T ES90309846T ES2062392T3 ES 2062392 T3 ES2062392 T3 ES 2062392T3 ES 90309846 T ES90309846 T ES 90309846T ES 90309846 T ES90309846 T ES 90309846T ES 2062392 T3 ES2062392 T3 ES 2062392T3
Authority
ES
Spain
Prior art keywords
fluticasone
medications including
salmeterol
including salmeterol
sequential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90309846T
Other languages
English (en)
Spanish (es)
Inventor
James Barry Douglas Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2062392(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2062392T3 publication Critical patent/ES2062392T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
ES90309846T 1989-09-08 1990-09-07 Medicamentos que comprenden salmeterol y fluticasona. Expired - Lifetime ES2062392T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
ES2062392T3 true ES2062392T3 (es) 1994-12-16

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90309846T Expired - Lifetime ES2062392T3 (es) 1989-09-08 1990-09-07 Medicamentos que comprenden salmeterol y fluticasona.

Country Status (20)

Country Link
EP (1) EP0416951B1 (show.php)
JP (1) JP3042867B2 (show.php)
AT (1) ATE99941T1 (show.php)
BE (1) BE1003053A3 (show.php)
CA (1) CA2024916C (show.php)
CH (1) CH680983C9 (show.php)
DE (2) DE19975040I2 (show.php)
DK (1) DK0416951T3 (show.php)
ES (1) ES2062392T3 (show.php)
FR (1) FR2651677B1 (show.php)
HK (1) HK18695A (show.php)
HU (1) HU211272A9 (show.php)
IE (1) IE65535B1 (show.php)
IL (1) IL95590A (show.php)
IT (1) IT1241996B (show.php)
LU (1) LU90392I2 (show.php)
NL (1) NL990012I2 (show.php)
NZ (1) NZ235221A (show.php)
PH (1) PH27594A (show.php)
SG (1) SG166294G (show.php)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
DK1383786T3 (da) 2001-04-30 2009-01-12 Glaxo Group Ltd Antiinflammatoriske 17-beta-carbothioatesterderivater af androstan med en cyklisk estergruppe i 17alfa-stilling
MXPA04002405A (es) 2001-09-14 2004-05-31 Glaxo Group Limetd Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
AU2003205855A1 (en) † 2002-02-04 2003-09-02 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
CA2477714C (en) * 2002-03-04 2011-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
HRP20050611B1 (hr) 2002-12-12 2013-12-20 Takeda Gmbh Kombinacijski lijek
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
EP1658063B1 (en) 2003-08-06 2014-03-12 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
AP2006003734A0 (en) * 2004-03-12 2006-10-31 Cipla Ltd Inhalation formulation
UA93031C2 (uk) 2004-07-16 2011-01-10 Алміралл, С.А. Інгалятор для порошкових медикаментів, фармацевтичний порошковий картридж для використання з інгалятором та спосіб використання інгалятора
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
AR076807A1 (es) 2009-05-29 2011-07-06 Pearl Therapeutics Inc Composiciones metodos y sistemas para el suministro de dos o mas agentes activos mediante las vias respiratorias. metodo de preparacion composicion
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
BR112015027017A2 (pt) * 2013-04-29 2017-07-25 Sanofi Sa composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
PH27594A (en) 1993-08-31
IL95590A0 (en) 1991-09-16
SG166294G (en) 1995-06-16
DE19975040I2 (de) 2006-07-13
DE69005951D1 (de) 1994-02-24
DK0416951T3 (da) 1994-02-14
FR2651677A1 (fr) 1991-03-15
IE65535B1 (en) 1995-11-01
IE903256A1 (en) 1991-03-13
JP3042867B2 (ja) 2000-05-22
IL95590A (en) 1996-06-18
EP0416951A1 (en) 1991-03-13
CH680983C9 (show.php) 2008-08-15
NL990012I1 (nl) 1999-07-01
ATE99941T1 (de) 1994-01-15
JPH03167120A (ja) 1991-07-19
FR2651677B1 (fr) 1993-08-06
LU90392I2 (fr) 1999-06-28
DE69005951T2 (de) 1994-05-26
CA2024916A1 (en) 1991-03-09
CH680983A5 (show.php) 1992-12-31
IT9048260A0 (it) 1990-09-07
NZ235221A (en) 1992-11-25
CA2024916C (en) 2002-07-09
NL990012I2 (nl) 1999-09-01
EP0416951B1 (en) 1994-01-12
HU211272A9 (en) 1995-11-28
HK18695A (en) 1995-02-17
CH680983C1 (show.php) 2008-06-25
BE1003053A3 (fr) 1991-11-05
IT9048260A1 (it) 1992-03-07
IT1241996B (it) 1994-02-02

Similar Documents

Publication Publication Date Title
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ES2123576T3 (es) Medicamentos.
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
DE3363321D1 (en) Long-lasting three layered pharmaceutical film preparations
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
DK0416950T3 (da) Medikamenter
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
DE69322251D1 (de) Medizinische zusammensetzung
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
IT1199180B (it) Riduzione degli effetti tossici cau sati da farmaci antrachinonici
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
MY111155A (en) Medicaments
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
RU93003454A (ru) Лекарственный препарат
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 416951

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: XINAFOATO DE SALMETEROL Y PROPIONATO DE FLUTICASONA (SERITIDE)

Spc suppl protection certif: C9900031

Filing date: 19990921

SPCG Supplementary protection certificate granted

Free format text: XINAFOATO DE SALMETEROL Y PROPIONATO DE FLUTICASONA (SERETIDE)

Spc suppl protection certif: C9900031

Filing date: 19990921

Expiry date: 20130907

Effective date: 20021119